A Phase 2 interventional study of SB11 PFS in Neovascular Age-related Macular Degeneration, Macular Edema and Retinal Vein Occlusion, sponsored by Samsung Bioepis Co., Ltd.. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-30.
Sponsored by Samsung Bioepis Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 58th largest by enrollment, is the only one that started in 2023, is one of 19 in phase 2, and was the 89th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Samsung Bioepis Co., Ltd. has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB11 PFS with intravitreal injection to subjects with nAMD or Macular Oedema Secondary to RVO.
This is an open-label, single group, single dose study in subjects with nAMD or Macular Oedema Secondary to RVO.
Screening and Day 1 can be performed on the same day. Subjects will receive ITV injection of SB11 PFS (0.5 mg ranibizumab in 0.05 mL) on Day 1, and follow up visit will be made on Day 1 (+2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received a single dose of SB11 PFS containing 0.5 mg ranibizumab in 0.05 mL solution.
Combination Product: SB11 PFS
SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
Also known as: Ranibizumab
Percentage of Successful Task Completions
Total of 12 tasks were evaluated, and the percentage of HCP's successful task completions were measured. Participating HCPs were allotted sufficient time to review the instructions for use (IFU) before preparing and administering the ITV injection on Day 1. HCP participants did not receive any additional training for the SB11 PFS prior to or during the study. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the primary endpoint was the percentage of successful tasks completion among total attempts in this study.
Time frame: Day 1
Percentage of Successful Completion on Critical Tasks
Total of 6 tasks were considered as critical task, and the percentage of HCP's successful completion on critical tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful critical tasks (total of 6) completion among total attempts in this study.
Time frame: Day 1
Percentage of Successful Completion on Essential Tasks
Total of 6 tasks were considered as essential task, and the percentage of HCP's successful completion on essential tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful essential tasks (total of 6) completion among total attempts in this study.
Time frame: Day 1
| Milestone | SB11 PFS - Subjects |
|---|---|
| Started | 34 |
| Completed | 34 |
| Not completed | 0 |
Total of 12 tasks were evaluated, and the percentage of HCP's successful task completions were measured. Participating HCPs were allotted sufficient time to review the instructions for use (IFU) before preparing and administering the ITV injection on Day 1. HCP participants did not receive any additional training for the SB11 PFS prior to or during the study. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the primary endpoint was the percentage of successful tasks completion among total attempts in this study.
| Percentage of successful task completion | SB11 PFS |
|---|---|
| Open the carton | 100 |
| Remove contents | 100 |
| Peel the lid off the blister pack | 100 |
| Carefully remove the PFS from the blister using aseptic technique | 100 |
| Remove the syringe cap | 100 |
| Attach a needle | 100 |
| Remove the needle cap | 100 |
| Set the dose | 100 |
| Insert the needle into the injection site | 100 |
| Press the plunger down to inject the medication | 100 |
| Remove the needle from the injection site | 100 |
| Dispose product | 100 |
Total of 6 tasks were considered as critical task, and the percentage of HCP's successful completion on critical tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful critical tasks (total of 6) completion among total attempts in this study.
| Percentage of successful task completion | SB11 PFS |
|---|---|
| Percentage of Successful Completion on Critical Tasks | 100 |
Total of 6 tasks were considered as essential task, and the percentage of HCP's successful completion on essential tasks were evaluated. "Percentage of successful task completions" was used as the unit of measure, as one SB11 PFS administration procedure is consisted of 12 tasks and the secondary endpoint was the percentage of successful essential tasks (total of 6) completion among total attempts in this study.
| Percentage of successful task completion | SB11 PFS |
|---|---|
| Percentage of Successful Completion on Essential Tasks | 100 |
Collected over Overall Period (Day 7). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SB11 PFS | 0/34 (0%) | 0/34 (0%) | 2/34 (5.9%) |
| Event | SB11 PFS |
|---|---|
| Ocular discomfortEye disorders | 1/34 |
| Ocular hyperaemiaEye disorders | 1/34 |
| NasopharyngitisInfections and infestations | 1/34 |
34 subjects were enrolled in the study.
| Age, Continuous(years) | SB11 PFS |
|---|---|
| Mean | 74.1 ± 7.45 |
| Sex: Female, Male(Participants) | SB11 PFS |
|---|---|
| Female | 21 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | SB11 PFS |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 34 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Main Indication(Participants) | SB11 PFS |
|---|---|
| Neovascular AMD | 32 |
| Macular Oedema Secondary to RVO | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2023 to primary completion in Nov 2023, 0 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 0 months is below that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab